JITC Digest August 2020


Inside this Issue:

Letter from the Editor

Dear JITC Readers,pedro-romero_1__1_.jpg

Welcome to this latest edition of the JITC digest. The papers highlighted this month offer exciting perspectives on the current state of the immunotherapy field as well as promising future directions for research.
Clinical oncologists can find a comprehensive overview of approved and emerging immunotherapies for multiple myeloma, including some of the new CAR T cell therapies currently in development, in the newest clinical practice guideline from SITC, by Nina Shah et al.
Promising clinical data on the use of checkpoint blockade for prostate cancer is provided in an original research article by Julie N Graff et al. The paper is the first to demonstrate durable responses with PD-1 inhibition in a subset of prostate cancer patients.
The identification of biomarkers to predict response to immunotherapy remains an important and ongoing area of study for our field. Two papers in this month’s digest highlight the key role that tumor metabolism plays in determining outcomes after immunotherapy, offering potential biomarkers for future study.
David Chardin and colleagues identify tumor metabolic parameters as measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) that are prognostic and predictive for outcomes after anti-PD-1 therapy for non-small cell lung cancer. Another immunometabolic biomarker is identified by Fangming Liu et al, who identify an association between FABP5-positive tumor infiltrating T cells and improved overall and recurrence-free survival in hepatocellular carcinoma.
New immunotherapeutic targets is another high-priority topic for research, and Marta Trüb and colleagues demonstrate promising in vitro anti-tumor properties with a novel fibroblast activation protein (FAP)-targeted 4-1BB agonist (FAP-4-1BBL).
Finally, do not miss an excellent review by Christopher A Chuckran et al of Neuropilin-1, which acts as a receptor ‘hub’ for sorting signals from diverse ligands to both promote regulatory T cell (Treg) stability in the tumor microenvironment and inhibit anti-tumor CD8+ T cell responses—the latest in the Immune Checkpoints Beyond PD-1 review series.
As always, you can also further your reading with highlights from other journals in JITC’s Reading List, selected this month by Claudia M Palena, PhD, of the NCI.
Best regards,

Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer

JITC Editor Picks

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Nina Shah, Jack Aiello, David E Avigan, Jesus G Berdeja, Ivan M Borrello, Ajai Chari, Adam D Cohen, Karthik Ganapathi, Lissa Gray, Damian Green, Amrita Krishnan, Yi Lin, Elisabet Manasanch, Nikhil C Munshi, Ajay K Nooka, Aaron P Rapoport, Eric L Smith, Ravi Vij, Madhav Dhodapkar
Journal for ImmunoTherapy of Cancer 2020;8:e000734 (12 July 2020)


Immunotherapy is currently playing a pivotal role in the treatment of multiple myeloma, with several approved antibody therapies and multiple other modalities including bispecific T cell engagers, CAR T cells and cancer vaccines in advanced clinical evaluation. Previously, in 2016, SITC published a consensus statement on immunotherapy for the treatment of hematologic malignancies, including acute leukemia, lymphoma and multiple myeloma. Recognizing the rapid pace of advancement of the field, and a need for practical guidance on how to incorporate the ever-growing number of immunotherapeutic agents into the treatment of multiple myeloma, SITC convened an expert panel encompassing perspectives from hematology, medical oncology, hematopathology, nursing and patient advocacy to provide evidence- and consensus-based recommendations for the oncology community on topics including patient selection, toxicity management, and quality of life considerations.

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

Julie N Graff, Tomasz M Beer, Joshi J Alumkal, Rachel E Slottke, William L Redmond, George V Thomas, Reid F Thompson, Mary A Wood, Yoshinobu Koguchi, Yiyi Chen, Emile Latour, Raymond C Bergan, Charles G Drake, Amy E Moran
Journal for ImmunoTherapy of Cancer 2020;8:e000642  (2 July 2020)



Checkpoint inhibition with anti-PD-1 monotherapy has shown minimal efficacy in prostate cancer, yet some studies have shown that patients with second-generation androgen receptor antagonist enzalutamide-resistant tumors display increased PD-L1 expression on circulating antigen-presenting cells. Hypothesizing that the addition of PD-1 inhibition after progression on androgen depravation could initiate a meaningful anti-cancer response, Julie N Graff et al enrolled 28 men with metastatic castration-resistant prostate cancer (mCRPC) in a single-arm phase II study of pembrolizumab given intravenously every 3 weeks for four doses along with enzalutamide. The primary endpoint was prostate-specific antigen decline of >=50%, which was achieved in five patients (18%). Median overall survival for the responders was 41.7 months (95% CI 22.16 to not reached), compared to 21.9 months (95% CI 14.7 to 28.4 months) for all patients. Three responders had baseline biopsies available, and none had detectable PD-L1 expression, though one had microsatellite instability high disease. Among patients with radiographically measurable disease, small discrepancies were observed between RECIST scoring and biopsied lesion-specific measurements. Exploratory biomarker analyses revealed significantly higher frequencies of granzyme B+ effector memory CD8+ T cells in responders compared to non- responders and a trend toward increased perforin+ effector memory CD8+ T cells in the responders. The study is the first to demonstrate durable responses with PD-1 checkpoint inhibition in a subset of patients with mCRPC and provide rationale for future trials of combination approaches.

Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study

David Chardin, Marie Paquet, Renaud Schiappa, Jacques Darcourt, Caroline Bailleux, Michel Poudenx, Aurélie Sciazza, Marius Ilie, Jonathan Benzaquen, Nicolas Martin, Josiane Otto, Olivier Humbert
Journal for ImmunoTherapy of Cancer 2020;8:e000645 (23 July 2020)


No reliable predictive and prognostic markers exist for patients treated with PD-(L)1 inhibitors for non-small cell lung cancer (NSCLC). David Chardin and colleagues prospectively enrolled 79 patients with NSCLC in a prospective trial to investigate the prognostic and predictive values for outcomes after anti-PD-1 therapy of baseline metabolic parameters from 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). For the 75 evaluable patients, high baseline metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were significantly associated with a lower overall survival (OS) and these parameters could also reliably predict early treatment discontinuation (ETD). Additionally, ETD was a strong surrogate marker for OS. In univariate analysis, patients who had not received previous chemotherapy had significantly higher MTV, while patients who had not received previous surgery or radiotherapy had significantly higher MTV and TLG. This is the largest prospective study to demonstrate that high baseline MTV is an independent predictive and prognostic factor in advanced NSCLC. Because 18F-FDG PET/CT is a noninvasive and whole-body scan that is available in routine practice, MTV could be a useful and simple tool to identify patients who may benefit from immunotherapy. Future trials stratifying patients by baseline FDG are needed to validate the utility of MTV as a prognostic and predictive biomarker.

Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma

Fangming Liu, Weiren Liu, Shuang Zhou, Chunhui Yang, Mengxin Tian, Guangshuai Jia, Han Wang, Bijun Zhu, Mingxiang Feng, Yan Lu, Tiankui Qiao, Xinxin Wang, Wei Cao, Xiangdong Wang, Yinghong Shi, Duojiao Wu
Journal for ImmunoTherapy of Cancer 2020;8:e000501 (1 July 2020)



T cell metabolism is critical for anti-cancer activity, and an understanding of altered energy usage by immune cell subsets in the tumor microenvironment may help inform the design of future immunotherapeutic strategies. To investigate metabolic perturbations in hepatocellular carcinoma (HCC), Fangming Liu and colleagues took advantage of single-cell RNA sequencing on 8047 sorted T cells from both HCC-adjacent healthy tissue and tumor cores. Of the eight stable cell clusters that emerged, two were identified as corresponding to exhausted CD8+ T cells. The gene encoding fatty acid binding protein FABP5 was specifically upregulated in the cluster of partially exhausted CD8+ T cells. Mitochondrial membrane potential and lipid uptake were increased in the cells with high FABP5 expression, though cellular neutral lipid content remained unchanged. Notable discrepancies in expression levels of tumor necrosis factor receptor superfamily mRNAs were observed between CD8+ T cell clusters, with roughly 85% of FABP5-positive T cells also expressing TNFRSF9, which encodes CD137 (4-1BB). Compared to CD28-based chimeric antigen receptor (CAR) T cells, CD137-costimulated CAR T cells displayed significant upregulation of genes associated with mitochondrial fatty acid oxidation as well as profoundly increased expression of peroxisome proliferator-activated receptor gamma (PPAR-gamma). Inhibition of PPAR-gamma impaired survival and proliferation of CD137-costimulated CAR T cells. The presence of T cells with upregulated FABP5 expression and increased lipid uptake was validated in tumor samples from patients with non-small cell lung cancer; furthermore, FABP5-positive tumor infiltrating T cells were linked with improved overall and recurrence-free survival in 118 patients with HCC. The study provides rationale for further investigation of FABP5 as a potential prognostic immunometabolic biomarker in larger, longitudinal studies.

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer

Marta Trüb, Franziska Uhlenbrock, Christina Claus, Petra Herzig, Martin Thelen, Vaios Karanikas, Marina Bacac, Maria Amann, Rosemarie Albrecht, Claudia Ferrara-Koller, Daniela Thommen, Sacha Rothschield, Spasenija Savic Prince, Kirsten D Mertz, Gieri Cathomas, Robert Rosenberg, Viola Heinzelmann-Schwarz, Mark Wiese, Didier Lardinois, Pablo Umana, Christian Klein, Heinz Laubli, Abhishek S Kashyap, Alfred Zippelius
Journal for ImmunoTherapy of Cancer 2020;8:e000238 (2 July 2020)



Ligation of the costimulatory receptor 4-1BB (CD137) by antigen-presenting cells or agonistic antibodies has been reported to enhance proliferation, effector functions, memory formation and survival in CD8+ T cells both in vitro and in vivo. However, single-agent systemic 4-1BB-targeting therapies have displayed disappointing efficacy or unmanageable toxicities in trials to date. Marta Trüb and colleagues investigated the immunostimulatory properties of a fibroblast activation protein (FAP)-targeted 4-1BB agonist (FAP-4-1BBL). In co-culture experiments with peripheral blood mononuclear cells from healthy donors and FAP-expressing fibroblasts, combination treatment with CD3-agonist antibody and FAP-4- 1BBL led to enhanced upregulation of activation markers CD25 and 4-1BB as well as proliferation marker Ki67. Exhausted tumor infiltrating lymphocytes (TILs) with high expression levels of inhibitory receptors PD-1, TIGIT, TIM-3, CD160, BTLA and Lag-3 that were freshly obtained from primary tumors of patients with non-small cell lung cancer and epithelial ovarian cancer displayed enhanced activation and effector functions after combination treatment with FAP-4-1BBL and either agonistic anti-CD3 or anti-tumor-antigen/anti-CD3 T cell bispecific antibodies. Both CD8+ and CD4+ TILs produced interferon gamma, IL-2 and tumor necrosis factor alpha after treatment with FAP-4-1BBL, and CD8+ TILs upregulated perforin production. Costimulation with FAP-4-1BBL also led to pronounced IL-13 secretion, as measured by high levels of the cytokine in TIL culture supernatants. Treatment with IL-13 led to detectable STAT6 phosphorylation in tumor cell lines and patient-derived cancer cells. Tumor cell lines exposed to supernatants from FAP-4-1BBL TILs significantly upregulated expression of active caspase 3. The work suggests IL-13 plays an important role in FAP-4-1BBL-mediated tumor cell apoptosis and offers rationale for a combination strategy to enhance the efficacy of bispecific antibodies against solid tumors.

Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy*

Christopher A Chuckran, Chang Liu, Tullia C Bruno, Creg J Workman, Dario AA Vignali
Journal for ImmunoTherapy of Cancer 2020;8:e000915 (15 July 2020)



In the efforts to identify new therapeutic targets for cancer immunotherapy, receptors that affect unique T cell subtypes and functions may offer substantial advantages for potential combinatorial strategies for checkpoint blockade. One promising potential target is Neutropilin-1 (NRP1), which acts as a receptor ‘hub’ for sorting signals from diverse ligands to both promote regulatory T cell (Treg) stability in the tumor microenvironment and inhibit anti-tumor CD8+ T cell responses. In a timely and comprehensive review, Christopher Chuckran and colleagues discuss the evidence that that NRP1, in addition to mediating important functions including self-tolerance and immune homeostasis, also plays a key role in regulating intratumoral Treg cells and CD8+ T cells in the context of cancer. In addition to the evidence that NRP1 is important for Treg trafficking to tumors and for maintaining intratumoral Treg cell function and phenotype, circulating NRP1+ Tregs are detected at high levels in patients with cancer—a unique observation among all known immune receptors. Although most studies to date have focused on NRP1’s role in angiogenesis, one anti-NRP1 monoclonal antibody, ASP1948 (human IgG4, Astellas Pharma Inc), is currently being clinically assessed in combination with nivolumab in a phase Ib trial (NCT03565445) for inhibitory effect on Treg cell function, and results are expected in 2022.

On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19

Thilo Gambichler, Judith Reuther, Christina H Scheel, Jürgen Christian Becker
Journal for ImmunoTherapy of Cancer 
2020;8:e001145 (1 July 2020)

Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung

Chul Kim, Stephen V Liu, Deepa S Subramaniam, Tisdrey Torres, Massimo Loda, Giuseppe Esposito, Giuseppe Giaccone
Journal for ImmunoTherapy of Cancer 
2020;8:e000980 (2 July 2020)

Molecular mechanisms of human herpes viruses inferring with host immune surveillance

Simon Jasinski-Bergner, Ofer Mandelboim, Barbara Seliger
Journal for ImmunoTherapy of Cancer 
2020;8:e000841 (2 July 2020)

Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency

Xionghao Pang, Juanjuan Qian, Hua Jin, Lei Zhang, Lin Lin, Yuli Wang, Yi Lei, Zeqiang Zhou, Meixiang Li, Henghui Zhang
Journal for ImmunoTherapy of Cancer 2020;8:e000463  (6 July 2020)
Case Report

BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy

Madhuri Koti, Alvaro Morales, Charles H Graham, David Robert Siemens
Journal for ImmunoTherapy of Cancer 2020;8:e001119  (6 July 2020)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

Bingxi He, Di Dong, Yunlang She, Caicun Zhou, Mengjie Fang, Yongbei Zhu, Henghui Zhang, Zhipei Huang, Tao Jiang, Jie Tian, Chang Chen
Journal for ImmunoTherapy of Cancer 2020;8:e000550  (6 July 2020)

Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma

Jean Hoffman-Censits, Sumanta Pal, Constanze Kaiser, Beiying Ding, Joaquim Bellmunt
Journal for ImmunoTherapy of Cancer 2020;8:e000419  (7 July 2020)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort

Byoung Chul Cho, Amaury Daste, Alain Ravaud, Sébastien Salas, Nicolas Isambert, Edward McClay, Ahmad Awada, Christian Borel, Laureen S Ojalvo, Christoph Helwig, P Alexander Rolfe, James L Gulley, Nicolas Penel
Journal for ImmunoTherapy of Cancer 
2020;8:e000664 (7 July 2020)

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Robert J Motzer, Bernard Escudier, David F McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles, Frede Donskov, Elizabeth R Plimack, Philippe Barthélémy, Hans J Hammers, Saby George, Viktor Grünwald, Camillo Porta, Victoria Neiman, Alain Ravaud, Toni K Choueiri, Brian I Rini, Pamela Salman, Christian K Kollmannsberger, Scott S Tykodi, Marc-Oliver Grimm, Howard Gurney, Raya Leibowitz-Amit, Poul F Geertsen, Asim Amin, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir
Journal for ImmunoTherapy of Cancer 2020;8:e000891  (12 July 2020)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis

Nazli Dizman, Yung Lyou, Nicholas Salgia, Paulo Gustavo Bergerot, JoAnn Hsu, Daniel Enriquez, Tyler Izatt, Jeffrey M Trent, Sara Byron, Sumanta Pal
Journal for ImmunoTherapy of Cancer 2020;8:e000953  (12 July 2020)

Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective

Casey Quinn, Louis P Garrison, Anja K Pownell, Michael B Atkins, Gérard de Pouvourville, Kevin Harrington, Paolo Antonio Ascierto, Phil McEwan, Samuel Wagner, John Borrill, Elise Wu
Journal for ImmunoTherapy of Cancer 2020;8:e000648  (12 July 2020)

Hematopoietic lineage-converted T cells carrying tumor-associated antigen-recognizing TCRs effectively kill tumor cells

Fangxiao Hu, Dehao Huang, Yuxuan Luo, Peiqing Zhou, Cui Lv, Kaitao Wang, Qitong Weng, Xiaofei Liu, Yuxian Guan, Yang Geng, Juan Du, Jiekai Chen, Jinyong Wang, Hongling Wu
Journal for ImmunoTherapy of Cancer 2020;8:e000498  (14 July 2020)
Short Report

Immunization associated with primary tumor growth leads to rejection of commonly used syngeneic tumors upon tumor rechallenge

Bruno Alicke, Klara Totpal, Jill M Schartner, Amy M Berkley, Sophie M Lehar, Aude-Hélène Capietto, Rafael A Cubas, Stephen E Gould
Journal for ImmunoTherapy of Cancer 2020;8:e000532  (15 July 2020)
Short Report

ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19

Riyue Bao, Kyle Hernandez, Lei Huang, Jason John Luke
Journal for ImmunoTherapy of Cancer 
2020;8:e001020  (15 July 2020)

Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells

Yuichi Iida, Rintaro Yoshikawa, Akihiko Murata, Hitoshi Kotani, Yasuhiro Kazuki, Mitsuo Oshimura, Yumi Matsuzaki, Mamoru Harada
Journal for ImmunoTherapy of Cancer 
2020;8:e000582 (16 July 2020)

Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer

Kenji Fujiwara, May Tun Saung, Hao Jing, Brian Herbst, MacKenzie Zarecki, Stephen Muth, Annie Wu, Elaine Bigelow, Linda Chen, Keyu Li, Neolle Jurcak, Alex B Blair, Ding Ding, Michael Wichroski, Jordan Blum, Nathan Cheadle, Jennifer Koenitzer, Lei Zheng
Journal for ImmunoTherapy of Cancer 
2020;8:e000351 (16 July 2020)

Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology

Ya-Qin Wang, Lei Chen, Yan-Ping Mao, Ying-Qing Li, Wei Jiang, Shuo-Yu Xu, Yu Zhang, Yu-Pei Chen, Xiao-Min Li, Qing-Mei He, Shi-Wei He, Xiao-Jing Yang, Yuan Lei, Yin Zhao, Jing-Ping Yun, Na Liu, Yingqin Li, Jun Ma
Journal for ImmunoTherapy of Cancer 
2020;8:e000334 (19 July 2020)

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy

Sjoerd T T Schetters, Ernesto Rodriguez, Laura J W Kruijssen, Matheus H W Crommentuijn, Louis Boon, Jan Van den Bossche, Joke M M Den Haan, Yvette Van Kooyk
Journal for ImmunoTherapy of Cancer
2020;8:e000588  (19 July 2020)

In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases

Paul A Clark, Raghava N Sriramaneni, Won Jong Jin, Justin C Jagodinsky, Amber M Bates, Abigail A Jaquish, Bryce R Anderson, Trang Le, Jonathan A Lubin, Ishan Chakravarty, Ian S Arthur, Clinton M Heinze, Emily I Guy, Jasdeep Kler, Kelsey A Klar, Peter M Carlson, Kyung Mann Kim, John S Kuo, Zachary S Morris
Journal for ImmunoTherapy of Cancer 2020;8:e000809  (19 July 2020)

A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth

María Alejandra Gleisner, Cristián Pereda, Andrés Tittarelli, Mariela Navarrete, Camila Fuentes, Ignacio Ávalos, Fabian Tempio, Juan Pablo Araya, María Inés Becker, Fermín Eduardo González, Mercedes Natalia López, Flavio Salazar-Onfray
Journal for ImmunoTherapy of Cancer 2020;8:e000999 (20 July 2020)

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

Souvik Dey, Erika Sutanto-Ward, Katharina L Kopp, James DuHadaway, Arpita Mondal, Dema Ghaban, Inés Lecoq, Mai-Britt Zocca, Lauren M F Merlo, Laura Mandik-Nayak, Mads Hald Andersen, Ayako Wakatsuki Pedersen, Alexander J Muller
Journal for ImmunoTherapy of Cancer 2020;8:e000605  (20 July 2020)

Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model

Sai Ping Lau, Nadine van Montfoort, Priscilla Kinderman, Melanie Lukkes, Larissa Klaase, Menno van Nimwegen, Mandy van Gulijk, Jasper Dumas, Dana A M Mustafa, Sanne L A Lievense, Christianne Groeneveldt, Ralph Stadhouders, Yunlei Li, Andrew Stubbs, Koen A Marijt, Heleen Vroman, Sjoerd H van der Burg, Joachim Aerts, Thorbald van Hall, Floris Dammeijer, Casper H J van Eijck
Journal for ImmunoTherapy of Cancer 2020;8:e000772  (20 July 2020)

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment

Ernesto Rossi, Giovanni Schinzari, Giampaolo Tortora
Journal for ImmunoTherapy of Cancer 
2020;8:e000952 (21 July 2020)

M1hot tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer

Eva M Garrido-Martin, Toby W P Mellows, James Clarke, Anusha-Preethi Ganesan, Oliver Wood, Angelica Cazaly, Gregory Seumois, Serena J Chee, Aiman Alzetani, Emma V King, Catherine C Hedrick, Gareth Thomas, Peter S Friedmann, Christian Hermann Ottensmeier, Pandurangan Vijayanand, Tilman Sanchez-Elsner
Journal for ImmunoTherapy of Cancer 
2020;8:e000778 (21 July 2020)

Checkpoint inhibitor-related renal vasculitis and use of rituximab

Omar Mamlouk, Jamie S Lin, Maen Abdelrahim, Amanda S Tchakarov, William F Glass, Umut Selamet, Maryam Buni, Noha Abdel-Wahab, Ala Abudayyeh
Journal for ImmunoTherapy of Cancer 2020;8:e000750 (22 July 2020)
Short Report

Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study

Chiun-Sheng Huang, Alice L Yu, Ling-Ming Tseng, Louis W C Chow, Ming-Feng Hou, Sara A Hurvitz, Richard B Schwab, James L Murray, Hsien-Kun Chang, Hong-Tai Chang, Shin-Cheh Chen, Sung-Bae Kim, Jung-Tung Hung, Shir-Hwa Ueng, Su-Hua Lee, Chwen-Cheng Chen, Hope S Rugo
Journal for ImmunoTherapy of Cancer 
2020;8:e000342 (22 July 2020)

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

Erika J Lampert, Ashley Cimino-Mathews, Joo Sang Lee, Jayakumar Nair, Min-Jung Lee, Akira Yuno, Daniel An, Jane B Trepel, Eytan Ruppin, Jung-Min Lee
Journal for ImmunoTherapy of Cancer 
2020;8:e000516 (23 June 2020)

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma

Yao Yao, Zhongyi Yan, Senlin Lian, Liangnian Wei, Chao Zhou, Dongju Feng, Yuan Zhang, Jianrong Yang, Ming Li, Yun Chen
Journal for ImmunoTherapy of Cancer 
2020;8:e000444 (27 July 2020)

SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity

Jia Wei, Jianping Zhao, Meifang Han, Fankai Meng, Jianfeng Zhou
Journal for ImmunoTherapy of Cancer 2020;8:e000137  (29 July 2020)
Case Report

Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity

Alexandra Borodovsky, Christine M Barbon, Yanjun Wang, Minwei Ye, Laura Prickett, Dinesh Chandra, Joseph Shaw, Nanhua Deng, Kris Sachsenmeier, James D Clarke, Bolan Linghu, Giles A Brown, James Brown, Miles Congreve, Robert KY Cheng, Andrew S Dore, Edward Hurrell, Wenlin Shao, Richard Woessner, Corinne Reimer, Lisa Drew, Stephen Fawell, Alwin G Schuller, Deanna A Mele
Journal for ImmunoTherapy of Cancer 2020;8:e000417  (29 July 2020)

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer

Kyoung-Ho Pyo, Sun Min Lim, Chae-Won Park, Ha-Ni Jo, Jae Hwan Kim, Mi-Ran Yun, Dohee Kim, Chun-Feng Xin, Wongeun Lee, Bianca Gheorghiu, Min Hee Hong, Hye Ryun Kim, Hyo Sup Shim, Mi Jang, Sung Sook Lee, Byoung Chul Cho
Journal for ImmunoTherapy of Cancer 2020;8:e000970  (29 July 2020)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

Sara Bedrose, Kevin Charles Miller, Lina Altameemi, Mohamed S Ali, Sameh Nassar, Naveen Garg, Marilyne Daher, Keith D Eaton, Jeffrey Thomas Yorio, Davey B Daniel, Matthew Campbell, Keith C Bible, Mabel Ryder, Ashish V Chintakuntlawar, Mouhammed Amir Habra
Journal for ImmunoTherapy of Cancer 2020;8:e001009  (30 July 2020)

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells

Kelly-Anne Masterman, Oscar L Haigh, Kirsteen M Tullett, Ingrid M Leal-Rojas, Carina Walpole, Frances E Pearson, Jonathon Cebon, Christopher Schmidt, Liam O'Brien, Nikita Rosendahl, Ghazal Daraj, Irina Caminschi, Eric H Gschweng, Roger P Hollis, Donald B Kohn, Mireille H Lahoud, Kristen J Radford
Journal for ImmunoTherapy of Cancer 
2020;8:e000691 (30 July 2020)

SITC Members Receive 50 Percent Submission Discount in 2020

*As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 50 percent discount on processing fees for all JITC articles accepted in 2020.